Want to see AU:OSX full AI Analyst Report?
OSX Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.05
Previous CloseN/A
Volume70.28K
Average Volume (3M)17.20M
Market Cap
AU$3.47M
Enterprise ValueAU$0.94
Total Cash (Recent Filing)AU$1.25M
Total Debt (Recent Filing)AU$74.39K
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Feb 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding693,592,900
10 Day Avg. Volume21,634,800
30 Day Avg. Volume17,195,343
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.70
Price to Sales (P/S)0.40
P/FCF Ratio-0.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained revenue expansion indicates increasing adoption of Osteopore’s regenerative implants and broader commercial reach. Continued growth provides a foundation for operating leverage if the company can scale sales faster than its cost base.
Healthy Gross MarginA healthy gross margin suggests the scaffold products retain meaningful economic value after production costs. This supports the potential for future profitability, provided the company controls operating expenses and expands procedure volumes.
Material Debt ReductionLower debt reduces interest and refinancing pressure and improves the company’s ability to direct resources toward commercial development. Although liquidity remains constrained, the smaller debt burden is a durable improvement in financial risk.
Bears Say
Persistent Net LossesOngoing substantial losses show that revenue growth has not yet translated into a viable earnings model. Without stronger operating leverage or cost reductions, continued losses may constrain investment capacity and require additional external funding.
Negative Operating Cash FlowRepeated negative operating and free cash flow indicates the business is not yet self-funding. Persistent cash burn can limit product development and market expansion while increasing reliance on capital raisings or other external financing.
Negative Shareholders’ EquityNegative equity reflects a weakened capital base and reduces financial flexibility. It can make future financing more difficult or dilutive and increases vulnerability if losses continue or operating funding needs rise.
Osteopore Ltd. News
OSX FAQ
What was Osteopore Ltd.’s price range in the past 12 months?
Osteopore Ltd. lowest share price was <AU$0.01 and its highest was AU$0.05 in the past 12 months.
What is Osteopore Ltd.’s market cap?
Osteopore Ltd.’s market cap is AU$3.47M.
When is Osteopore Ltd.’s upcoming earnings report date?
Osteopore Ltd.’s upcoming earnings report date is Feb 26, 2027 which is in 170 days.
How were Osteopore Ltd.’s earnings last quarter?
Osteopore Ltd. released its earnings results on Aug 31, 2026. The company reported -AU$0.004 earnings per share for the quarter.
Is Osteopore Ltd. overvalued?
According to Wall Street analysts Osteopore Ltd.’s price is currently Overvalued.
Does Osteopore Ltd. pay dividends?
Osteopore Ltd. does not currently pay dividends.
What is Osteopore Ltd.’s EPS estimate?
Osteopore Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Osteopore Ltd. have?
Osteopore Ltd. has 693,592,900 shares outstanding.
What happened to Osteopore Ltd.’s price movement after its last earnings report?
Osteopore Ltd. reported an EPS of -AU$0.004 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Osteopore Ltd.?
Currently, no hedge funds are holding shares in AU:OSX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Osteopore Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.17%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Osteopore Ltd.
Established in Singapore in 2003, Osteopore Limited focuses on engineering, manufacturing, and globally commercializing bioresorbable polymer implants. These advanced devices are utilized in neurosurgical, orthopedic, and maxillofacial operations throughout Singapore, Australia, and other international regions. The company's core innovation involves employing 3D printing with bioresorbable materials to create custom, micro-structured scaffolds specifically designed to foster bone regeneration. Its product portfolio includes Osteoplug, a resorbable implant for sealing trephination burr holes during neurosurgery, and Osteomesh, another resorbable implant used in craniofacial surgery to mend various fractures, including orbital floor injuries, and to fill surgical voids. Additionally, Osteopore has forged a collaborative partnership with Livingstone Health Holding Limited to jointly pioneer new products and applications for bone and tissue regeneration.